AMRX
Amneal Pharmaceuticals, Inc.
19.80$
+2.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 62.5% | 63.5% | 63.9% | 64.4% | 61.6% | 64.0% | 63.2% | 60.5% | 65.1% | 63.5% | 55.7% | 58.0% | 60.7% | |
| 37.5% | 36.5% | 36.1% | 35.6% | 38.4% | 36.0% | 36.8% | 39.5% | 34.9% | 36.5% | 44.3% | 42.0% | 39.3% | |
| 6.8% | 7.5% | 6.0% | 5.3% | 8.7% | 7.7% | 6.0% | 6.9% | 8.1% | 4.3% | 5.3% | 5.2% | 5.7% | |
| 18.2% | 15.7% | 17.1% | 16.6% | 16.9% | 12.9% | 17.0% | 17.2% | 17.6% | 18.0% | 25.8% | 18.7% | 19.9% | |
| 25.3% | 34.2% | 37.7% | 22.0% | 25.7% | 25.6% | 22.4% | 24.1% | 34.9% | 22.4% | 24.5% | 23.7% | 26.4% | |
| 12.2% | 2.3% | -1.6% | 13.6% | 12.6% | 10.4% | 14.4% | 15.4% | 0.0% | 14.1% | 19.8% | 18.3% | 12.9% | |
| 8.2% | 9.7% | 10.0% | 9.4% | 9.3% | 8.4% | 8.2% | 9.0% | 8.0% | 6.9% | 7.4% | 6.9% | 7.3% | |
| 3.7% | -13.5% | -11.5% | 2.9% | 2.2% | -2.1% | 5.4% | 7.1% | -0.7% | 6.8% | 11.1% | 8.9% | 6.5% | |
| -0.3% | 1.6% | 0.9% | 0.5% | 0.5% | 0.7% | 1.9% | 2.2% | -3.0% | 0.7% | 0.3% | 0.2% | -0.5% | |
| 1.6% | -16.0% | -13.9% | 0.9% | 0.0% | -4.3% | 1.8% | 3.1% | 0.3% | 4.3% | 8.6% | 7.2% | 5.0% | |
| 21.1% | 5.4% | 6.9% | 20.2% | 19.9% | 15.4% | 22.2% | 24.4% | 14.2% | 19.7% | 25.8% | 24.3% | 20.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.